Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carl Willis

Hematology & Oncology Nashville, TN Medical Doctor

NPI 1154376259 CMS profile 1050924

322 22Nd Ave N Ste 400, Nashville, TN 37203

Open in the dashboard

General payments

$21,477

983 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carl Willis of Nashville, TN is reported in the CMS Open Payments database as having received $21,477 across 983 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,030 124
2024 General $3,210 135
2023 General $3,685 146
2022 General $3,540 156
2021 General $2,883 146
2020 General $2,718 138
2019 General $2,410 138

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carl Willis
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Carl Willis were reported at $3,030. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Carl Willis Hematology & Oncology median Middle half National median
2019 $2,410 $529 $121–$2,516 $163
2020 $2,718 $339 $82–$2,213 $114
2021 $2,883 $263 $49–$1,965 $132
2022 $3,540 $416 $103–$2,395 $149
2023 $3,685 $542 $125–$2,646 $160
2024 $3,210 $692 $141–$3,008 $164
2025 $3,030 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,657 70 payments
  2. Merck Sharp & Dohme Corporation $1,481 68 payments
  3. Novartis Pharmaceuticals Corporation $1,255 62 payments
  4. E.R. Squibb & Sons, L.L.C. $1,116 64 payments
  5. Janssen Biotech, Inc. $1,112 47 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $948 32 payments
  7. Pfizer Inc. $809 49 payments
  8. Genentech USA, Inc. $640 34 payments
  9. Incyte Corporation $615 26 payments
  10. GlaxoSmithKline, LLC. $600 28 payments
  11. Other $11,245 503 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $20,507 962 payments
  2. Education $970 21 payments
Products named General payments · program years 2019–2025
  1. KEYTRUDA $1,295 60 payments
  2. OPDIVO $645 38 payments
  3. LIBTAYO $544 25 payments
  4. DARZALEX $522 25 payments
  5. KISQALI $515 25 payments
  6. Lenvima $512 21 payments
  7. IMBRUVICA $501 20 payments
  8. CALQUENCE $458 21 payments
  9. ENHERTU $441 19 payments
  10. LYNPARZA $414 18 payments
  11. Other $19,197 929 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

644

Median for Medical Oncology: 414

Drug cost

$1,069,893

Median for Medical Oncology: $849,427

Branded share of claims

18.3%

Median for Medical Oncology: 28.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ibrance Palbociclib Brand 35 $525,179
Brukinsa Zanubrutinib Brand 13 $183,953
Erleada Apalutamide Brand 11 $167,317
Revlimid Lenalidomide Brand 13 $164,920
Xarelto Rivaroxaban Brand 20 $17,936
Letrozole Generic 221 $4,980
Anastrozole Generic 132 $2,570
Exemestane Generic 14 $1,040
Tamoxifen Citrate Generic 24 $544
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 13 $253

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 91 billing codes

Paid by Medicare

$691,062

Of which drugs: $633,760

Medicare patients

185

Average age 73

Services billed

40,195

149 women, 36 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 75%
Arthritis 46%
Diabetes 27%
Depression 24%
Ischemic heart disease 23%
Chronic kidney disease 23%
Osteoporosis 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 26 3,600 $71,883
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 18 750 $68
Injection, diphenhydramine hcl, up to 50 mg J1200 Office 14 65 $43

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 81 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KEYTRUDA
$165 — —
Lenvima
$158 — —
LYNPARZA
$104 — —
KISQALI
$102 — —
REBLOZYL
$92 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 81 with Patron

Records

983 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record